Monensin is an antiprotozoal agent produced by Streptomyces cinnamonensis. It has an inhibitory effect on the Wnt β-catenin signaling cascade. Monensin is a prospective anticancer drug for the therapy of neoplasia with deregulated Wnt signaling.
Monensin B is a polyketide compound derived from the bacterium Streptomyces cinnamonensis. Its production involves the fermentation of Streptomyces cinnamonensis, resulting in a mixture of Monensin A and Monensin B. The ratio of these two compounds depends on the concentrations of ethylmalonyl-CoA and methylmalonyl-CoA.